Showing Results for
- Academic Journals (95)
Search Results
- 95
Academic Journals
- 95
-
From:Reactions Weekly (Issue 1309)A 46-year-old woman, who was receiving long-term therapy with leflunomide for rheumatoid arthritis (RA), presented with a 4-week history of severe diarrhoea and a 5kg weight loss. Her RA had been managed with IM...
-
From:Expert Review of Clinical Immunology (Vol. 7, Issue 3) Peer-ReviewedAuthor(s): W James Chon 1 , Michelle A Josephson [[dagger]â ] 2 Keywords : BK virus nephropathy; chronic allograft failure; leflunomide; renal transplantation Renal transplantation represents the best...
-
From:Expert Review of Clinical Immunology (Vol. 2, Issue 1) Peer-ReviewedAuthor(s): Gary Kunkel [[dagger]] 1 , Grant W Cannon 1 Keywords: clinical trials; juvenile rheumatoid arthritis; leflunomide; rheumatoid arthritis Rheumatoid arthritis (RA) is a chronic, disabling disease that...
-
From:Annals of the Rheumatic Diseases (Vol. 59, Issue 11) Peer-ReviewedAbstract Leflunomide is a selective inhibitor of de novo pyrimidine synthesis. In phase II and III clinical trials of active rheumatoid arthritis, leflunomide was shown to improve primary and secondary outcome...
-
From:Expert Review of Pharmacoeconomics & Outcomes Research (Vol. 4, Issue 6) Peer-ReviewedMacro-level economic evaluations of drugs are expected to provide useful information for making the decision of whether to approve a newly developed drug as a first-line treatment. Leflunomide has been hoped to be an...
-
From:PLoS ONE (Vol. 5, Issue 8) Peer-ReviewedBackground The pathogenesis of immunodeficiency due to human immunodeficiency virus (HIV)-1 is incompletely understood, but immune activation is believed to play a central role. Immunomodulatory agents that decrease...
-
From:PLoS ONE (Vol. 7, Issue 9) Peer-ReviewedBackground Idiopathic membranous nephropathy (IMN) is the most common pathological type for nephrotic syndrome in adults in western countries and China. The benefits and harms of immunosuppressive treatment in IMN...
-
From:Reactions Weekly (Issue 1311)The US FDA is adding information regarding the risk of serious liver injury to the Boxed Warning of the rheumatoid arthritis treatment, leflunomide [Arava]. While a bolded warning statement regarding severe liver...
-
From:Reactions Weekly (Issue 1291)The European CHMP has reported that it has adopted amendments to the Summaries of Product Characteristics (SPCs) for Revlimid [lenalidomide], Arava [leflunomide], Ivemend [fosaprepitant], Thalidomide Celgene...
-
From:Pharmacogenomics (Vol. 13, Issue 2) Peer-ReviewedAuthor(s): Catherine O'Doherty 1 , Matthew Schnabl 1 , Llewellyn Spargo 2 , Leslie G Cleland 2 3 , Michael James 2 3 , Susanna M Proudman 2 3 , Michael D Wiese [*] 4 KEYWORDS : DHODH; leflunomide;...
-
From:Reactions Weekly (Issue 1340)[*] [S] A 16-year-old girl developed drug hypersensitivity syndrome, which later manifested as hypothyroidism, during treatment with leflunomide. The girl was admitted with a skin rash and fever, which had...
-
From:Indian Journal of Dermatology (Vol. 55, Issue 4) Peer-ReviewedByline: Veeranna. Shastry, Jayadev. Betkerur Sir, A sixteen year-old girl presented with a history of swelling of the face and extremities, dryness of the skin, slurring of speech, and weight gain of one month's...
-
From:Future Rheumatology (Vol. 1, Issue 6) Peer-ReviewedAuthor(s): Earl Silverman [[dagger]] 1 , Vibeke Strand 2 Keywords: drug therapy; drug trials; inflammatory arthritis; juvenile idiopathic arthritis; juvenile rheumatoid arthritis; leflunomide; outcomes; pediatrics...
-
From:Annals of the Rheumatic Diseases (Vol. 61, Issue 10) Peer-ReviewedWere read with great interest the article by Scott and colleagues, (1) in which they report radiological improvement or halting of disease progression with leflunomide treatment in a group of patients with rheumatoid...
-
From:Clin Alert (Vol. 44, Issue 3)No. 34 A 62-year-old male with a 15-month history of rheumatoid arthritis (RA) presented with acute respiratory insufficiency while on leflunomide. Drug history included steroids (10-25 mg/d; months 1 - 15) and...
-
From:CMAJ: Canadian Medical Association Journal (Vol. 182, Issue 9) Peer-ReviewedLeflunomide warning: Health Canada has issued an adverse reaction warning that peripheral neuropathy has been associated with the disease-modifying antirheumatic drug leflunomide (Arava). "Signs and symptoms include...
-
From:Pharmaceutical Medicine (Vol. 25, Issue 2) Peer-ReviewedThree studies presented at the American Association for the Study of Liver Diseases' 61st Annual Meeting examined the issue of drug-induced liver injury (DILI). History of DILI Not Linked to Future Episodes In the...
-
From:Reactions Weekly (Issue 1244)[S] A 53-year-old woman with rheumatoid arthritis (RA) developed interstitial pneumonia while receiving leflunomide and subsequently died. Following diagnosis of RA in April 2005, the woman received methotrexate...
-
From:PLoS ONE (Vol. 8, Issue 8) Peer-ReviewedLeflunomide as an immunosuppressive drug is generally used in the treatment of rheumatoid arthritis. It inhibits DHODH (dihydroorotate dehydrogenase ), which is one of the essential enzymes in the de novo pyrimidine...
-
From:Reactions Weekly (Issue 1260)A study conducted by German researchers found a 6-fold increase in the incidence of pancreatic cancer in patient receiving leflunomide for rheumatoid arthritis (RA). The study was presented at the Annual Congress of the...